Highlights:
Seven subjects in cohort three intravenously dosed; RECCE® 327 at 500mg indicating to be safe and well tolerated Minimum recruited subjects met (7); additional three (3) at this milestone requested to maximize key data set â expected within two weeks Independent Safety Committee to review at study completion â expect recommendation to proceed â cohort four recruitment underway
SYDNEY, Australia, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE...
>>> Read more: Recce Pharmaceuticals Announces Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
Seven subjects in cohort three intravenously dosed; RECCE® 327 at 500mg indicating to be safe and well tolerated Minimum recruited subjects met (7); additional three (3) at this milestone requested to maximize key data set â expected within two weeks Independent Safety Committee to review at study completion â expect recommendation to proceed â cohort four recruitment underway
SYDNEY, Australia, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE...
>>> Read more: Recce Pharmaceuticals Announces Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
